Shuttle Pharma to Attend Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Shuttle Pharmaceuticals Holdings, Inc., headquartered in Gaithersburg, Maryland, is a specialty pharmaceutical company committed to enhancing the outcomes of cancer patients undergoing radiation therapy (RT). On May 22, 2024, the company announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will participate in the Lytham Partners Spring 2024 Investor Conference. The event, which will be held virtually on Thursday, May 30, 2024, will feature a webcasted presentation by Dr. Dritschilo and one-on-one meetings with investors.

Dr. Dritschilo’s presentation will focus on the company's latest advancements, particularly the progress in its Phase 2 Clinical Trial of Ropidoxuridine. This drug is being tested for its efficacy in treating glioblastoma, a severe and currently incurable brain cancer. The presentation will also cover the initiatives of Shuttle Pharmaceuticals' subsidiary, Shuttle Diagnostics, Inc., which is working on developing predictive biomarkers to determine prostate cancer outcomes post-radiation therapy, as well as a novel PSMA ligand for theranostic applications.

The webcast of Dr. Dritschilo’s presentation is scheduled for 11:00 am ET on May 30, 2024. Interested parties can view the webcast by visiting the conference's home page or accessing a direct link provided by the company. A replay of the webcast will be available after the event for those who cannot attend the live session.

During the conference, Shuttle Pharmaceuticals' management will engage in virtual one-on-one meetings with investors. These meetings offer an opportunity for investors to interact directly with the company's leadership and gain deeper insights into its strategic initiatives and milestones. Investors who wish to arrange a meeting can contact Lytham Partners or register for the event through the provided links.

Shuttle Pharmaceuticals was established in 2012 by faculty members of Georgetown University Medical Center. The company dedicates itself to improving cancer treatment outcomes by developing therapies that enhance the effectiveness of RT while minimizing its side effects. RT is a well-established method for treating various cancers, and Shuttle Pharmaceuticals aims to increase cure rates, extend patient survival, and improve quality of life by creating radiation sensitizers. These sensitizers are designed to be used either as a primary treatment or in conjunction with other modalities such as surgery, chemotherapy, and immunotherapy.

In summary, Shuttle Pharmaceuticals is progressing in its mission to revolutionize cancer treatment through innovative research and development. The upcoming presentation at the Lytham Partners Spring 2024 Investor Conference will provide valuable updates on the company’s clinical trials and future plans, particularly regarding the treatment of glioblastoma and prostate cancer.